vs
Side-by-side financial comparison of Oportun Financial Corp (OPRT) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Oportun Financial Corp is the larger business by last-quarter revenue ($247.7M vs $196.9M, roughly 1.3× Pacira BioSciences, Inc.). On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.1% vs -1.3%). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (8.5% CAGR vs -0.5%).
Oportun Financial Corp is a US-based fintech firm that provides accessible, responsible financial services including personal loans, credit cards, and savings products to underserved low-to-moderate income consumers, many with limited or no credit history, leveraging proprietary AI underwriting to deliver fair terms while mitigating operational risk.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
OPRT vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.7M | $196.9M |
| Net Profit | $3.4M | — |
| Gross Margin | — | 79.5% |
| Operating Margin | 2.6% | 1.2% |
| Net Margin | 1.4% | — |
| Revenue YoY | -1.3% | 5.1% |
| Net Profit YoY | -61.0% | — |
| EPS (diluted) | $0.07 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.7M | $196.9M | ||
| Q3 25 | $238.7M | $179.5M | ||
| Q2 25 | $234.3M | $181.1M | ||
| Q1 25 | $235.9M | $168.9M | ||
| Q4 24 | $250.9M | $187.3M | ||
| Q3 24 | $250.0M | $168.6M | ||
| Q2 24 | $250.4M | $178.0M | ||
| Q1 24 | $250.5M | $167.1M |
| Q4 25 | $3.4M | — | ||
| Q3 25 | $5.2M | $5.4M | ||
| Q2 25 | $6.9M | $-4.8M | ||
| Q1 25 | $9.8M | $4.8M | ||
| Q4 24 | $8.7M | — | ||
| Q3 24 | $-30.0M | $-143.5M | ||
| Q2 24 | $-31.0M | $18.9M | ||
| Q1 24 | $-26.4M | $9.0M |
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% | ||
| Q1 24 | — | 71.6% |
| Q4 25 | 2.6% | 1.2% | ||
| Q3 25 | 6.0% | 3.5% | ||
| Q2 25 | 4.3% | 4.7% | ||
| Q1 25 | 5.6% | 1.2% | ||
| Q4 24 | 89.6% | 13.2% | ||
| Q3 24 | -15.8% | -82.8% | ||
| Q2 24 | -19.6% | 15.9% | ||
| Q1 24 | -12.2% | 7.9% |
| Q4 25 | 1.4% | — | ||
| Q3 25 | 2.2% | 3.0% | ||
| Q2 25 | 2.9% | -2.7% | ||
| Q1 25 | 4.1% | 2.8% | ||
| Q4 24 | 200.1% | — | ||
| Q3 24 | -12.0% | -85.1% | ||
| Q2 24 | -12.4% | 10.6% | ||
| Q1 24 | -10.6% | 5.4% |
| Q4 25 | $0.07 | $0.05 | ||
| Q3 25 | $0.11 | $0.12 | ||
| Q2 25 | $0.14 | $-0.11 | ||
| Q1 25 | $0.21 | $0.10 | ||
| Q4 24 | $0.26 | $0.38 | ||
| Q3 24 | $-0.75 | $-3.11 | ||
| Q2 24 | $-0.78 | $0.39 | ||
| Q1 24 | $-0.68 | $0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $105.5M | $238.4M |
| Total DebtLower is stronger | — | $372.2M |
| Stockholders' EquityBook value | $390.1M | $693.1M |
| Total Assets | $3.3B | $1.3B |
| Debt / EquityLower = less leverage | — | 0.54× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $105.5M | $238.4M | ||
| Q3 25 | $104.6M | $246.3M | ||
| Q2 25 | $96.8M | $445.9M | ||
| Q1 25 | $78.5M | $493.6M | ||
| Q4 24 | $60.0M | $484.6M | ||
| Q3 24 | $71.8M | $453.8M | ||
| Q2 24 | $72.9M | $404.2M | ||
| Q1 24 | $69.2M | $325.9M |
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $390.1M | $693.1M | ||
| Q3 25 | $383.9M | $727.2M | ||
| Q2 25 | $376.0M | $757.8M | ||
| Q1 25 | $366.1M | $798.5M | ||
| Q4 24 | $353.8M | $778.3M | ||
| Q3 24 | $327.6M | $749.6M | ||
| Q2 24 | $354.1M | $879.3M | ||
| Q1 24 | $382.0M | $892.2M |
| Q4 25 | $3.3B | $1.3B | ||
| Q3 25 | $3.2B | $1.3B | ||
| Q2 25 | $3.2B | $1.5B | ||
| Q1 25 | $3.2B | $1.6B | ||
| Q4 24 | $3.2B | $1.6B | ||
| Q3 24 | $3.3B | $1.5B | ||
| Q2 24 | $3.3B | $1.6B | ||
| Q1 24 | $3.3B | $1.6B |
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $413.4M | $43.7M |
| Free Cash FlowOCF − Capex | — | $43.5M |
| FCF MarginFCF / Revenue | — | 22.1% |
| Capex IntensityCapex / Revenue | — | 0.1% |
| Cash ConversionOCF / Net Profit | 121.45× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $136.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $413.4M | $43.7M | ||
| Q3 25 | $99.0M | $60.8M | ||
| Q2 25 | $104.5M | $12.0M | ||
| Q1 25 | $101.0M | $35.5M | ||
| Q4 24 | $393.5M | $33.1M | ||
| Q3 24 | $108.5M | $53.9M | ||
| Q2 24 | $107.7M | $53.2M | ||
| Q1 24 | $85.9M | $49.1M |
| Q4 25 | — | $43.5M | ||
| Q3 25 | — | $57.0M | ||
| Q2 25 | — | $9.3M | ||
| Q1 25 | — | $26.9M | ||
| Q4 24 | — | $31.0M | ||
| Q3 24 | — | $49.8M | ||
| Q2 24 | — | $51.6M | ||
| Q1 24 | — | $46.3M |
| Q4 25 | — | 22.1% | ||
| Q3 25 | — | 31.7% | ||
| Q2 25 | — | 5.1% | ||
| Q1 25 | — | 15.9% | ||
| Q4 24 | — | 16.6% | ||
| Q3 24 | — | 29.6% | ||
| Q2 24 | — | 29.0% | ||
| Q1 24 | — | 27.7% |
| Q4 25 | — | 0.1% | ||
| Q3 25 | — | 2.2% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 5.1% | ||
| Q4 24 | — | 1.1% | ||
| Q3 24 | — | 2.4% | ||
| Q2 24 | — | 0.9% | ||
| Q1 24 | — | 1.7% |
| Q4 25 | 121.45× | — | ||
| Q3 25 | 19.05× | 11.20× | ||
| Q2 25 | 15.20× | — | ||
| Q1 25 | 10.34× | 7.37× | ||
| Q4 24 | 45.04× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.82× | ||
| Q1 24 | — | 5.47× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
OPRT
Segment breakdown not available.
PCRX
| EXPAREL | $155.8M | 79% |
| ZILRETTA | $33.0M | 17% |
| Iovera | $7.0M | 4% |
